{"id":822722,"date":"2026-06-30T18:08:01","date_gmt":"2026-06-30T18:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=822722"},"modified":"2026-06-30T18:08:01","modified_gmt":"2026-06-30T18:08:01","slug":"nuclear-medicine-market-to-reach-2101-billion-by-2030-driven-by-growth-in-molecular-imaging-and-theranostics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nuclear-medicine-market-to-reach-2101-billion-by-2030-driven-by-growth-in-molecular-imaging-and-theranostics_822722.html","title":{"rendered":"Nuclear Medicine Market to Reach $21.01 Billion by 2030, Driven by Growth in Molecular Imaging and Theranostics"},"content":{"rendered":"
\"Nuclear<\/a><\/div>\n
Nuclear Medicine Market by Type [SPECT (Tc-99m, I-123, Ga-67), PET (F-18), Alpha Emitters, Beta Emitters (Y-90, Lu-177), Brachytherapy], Application (Oncology, Cardiology, Neurology), Procedure, End User (Imaging Center, Hospital), and Region -Global Forecast to 2030<\/div>\n

According to MarketsandMarkets™, <\/strong>The global nuclear medicine market<\/a><\/strong> is projected to grow from USD 10.41 billion in 2025 to USD 21.01 billion by 2030, at a CAGR of 15.1% during the forecast period. This robust growth is driven by the increasing adoption of molecular imaging, rising demand for theranostics, and continuous advancements in radiopharmaceutical development.<\/p>\n

Browse 450 market data Tables and 50 Figures spread through 342 Pages and in-depth TOC on<\/strong> “<\/strong>Nuclear Medicine Market “.<\/strong><\/p>\n

Download PDF Brochure: https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=417<\/a><\/strong><\/p>\n

The development of novel PET and SPECT tracers, targeted radionuclide therapies, and advancements in imaging systems are significantly enhancing diagnostic accuracy and therapeutic outcomes. Additionally, automation in radiopharmacy processes and improvements in isotope production and supply chains are supporting the scalability and accessibility of nuclear medicine globally.<\/p>\n

The growing focus on precision and personalized medicine, coupled with increased investments in healthcare infrastructure and favorable regulatory approvals for innovative radiopharmaceuticals, is further accelerating market expansion.<\/p>\n

Diagnostic Segment Leads the Market<\/strong><\/p>\n

The diagnostic nuclear medicine segment accounted for a larger share of the market in 2024. This dominance is attributed to the widespread use of PET and SPECT imaging technologies for accurate, non-invasive disease detection and monitoring.<\/p>\n

Continuous advancements in radiotracer development and imaging technologies have improved diagnostic precision and clinical utility. Additionally, expanded access to diagnostic radiopharmaceuticals and the integration of advanced analytics with imaging systems are strengthening the segment’s leadership.<\/p>\n

Hospitals Segment to Witness Fastest Growth<\/strong><\/p>\n

By end user, the hospitals segment is projected to register the highest growth during the forecast period. Increasing investments in advanced imaging infrastructure and the expansion of in-house nuclear medicine departments are key factors driving this growth.<\/p>\n

Hospitals are increasingly integrating radiopharmacy capabilities with diagnostic services to enhance workflow efficiency, improve clinical decision-making, and support comprehensive patient care. These developments are expected to significantly boost segment growth over the coming years.<\/p>\n

Request Sample Pages: https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=417<\/a><\/strong><\/p>\n

North America Dominates the Global Market<\/strong><\/p>\n

North America is expected to dominate the nuclear medicine market throughout the forecast period. The region benefits from a well-established radiopharmaceutical manufacturing and distribution ecosystem, strong healthcare infrastructure, and high adoption of advanced imaging technologies.<\/p>\n

The presence of leading market players, extensive nuclear pharmacy networks, and continuous regulatory approvals for new diagnostic and therapeutic isotopes further support market growth. Additionally, increasing access to nuclear medicine services across hospitals and diagnostic centers reinforces the region’s leadership position.<\/p>\n

Competitive Landscape<\/strong><\/p>\n

Key players in the nuclear medicine market include GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), Lantheus Holdings, Inc. (US), Novartis AG (Switzerland), Jubilant Pharmova Limited (India), Bracco Imaging S.p.A. (Italy), PharmaLogic Holdings Corp. (US), NTP Radioisotopes SOC Ltd. (South Africa), Nordion Inc. (Canada), Siemens Healthineers AG (Germany), NorthStar Medical Radioisotopes, LLC (US), Eckert & Ziegler (Germany), Isotope JSC (Russia), Global Medical Solutions (US), Telix Pharmaceuticals Limited (Australia), PDRadiopharma Inc. (Japan), ITM Isotope Technologies Munich SE (Germany), BWX Technologies Inc. (US), SHINE Technologies, LLC (US), Isotopia (Israel), Institute of Isotopes (Hungary), China Isotope & Radiation Corporation (China), and IRE ELiT (Turkey).<\/p>\n

These companies are actively engaged in product innovation, strategic collaborations, and expansion of radiopharmaceutical production capabilities to strengthen their market position and meet growing global demand.<\/p>\n

Related Reports:<\/strong><\/p>\n

Nuclear Medicine Equipment Market<\/a> – Global Forecast to 2030<\/strong><\/p>\n

Radiation Detection, Monitoring & Safety Market<\/a> – Global Forecast to 2031<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets\u2122 Research Private Ltd.<\/a>
Contact Person:<\/strong> Mr. Rohan Salgarkar
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City:<\/strong> Florida
State:<\/strong> Florida
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/radiopharmaceuticals-market-417.html<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Nuclear Medicine Market by Type [SPECT (Tc-99m, I-123, Ga-67), PET (F-18), Alpha Emitters, Beta Emitters (Y-90, Lu-177), Brachytherapy], Application (Oncology, Cardiology, Neurology), Procedure, End User (Imaging Center, Hospital), and Region -Global Forecast to 2030 According to MarketsandMarkets™, The global nuclear … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,411,404],"tags":[],"class_list":["post-822722","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Technology","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/822722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=822722"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/822722\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=822722"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=822722"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=822722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}